This story first appeared in Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox. I apologize for this depressing ...

Biotech venture capital is on the precipice of a generational shift. At least, that’s according to the crowd of younger firm founders edging their way in. There’s long been a small batch of ...

Boston biotech Kojin Therapeutics is closing its doors, citing four funding challenges and a few valuable lessons learned. The cancer- and autoimmune-focused company will wind down operations over ...

We recently compiled a list of the 10 Cheap Biotech Stocks to Invest in Now. In this article, we are going to take a look at where Voyager Therapeutics, Inc. (NASDAQ:VYGR) stands against the other ...